From the Departments of Electrical and Computer Engineering.
Bioengineering, University of Texas at Dallas, Richardson, TX.
Invest Radiol. 2022 Apr 1;57(4):222-232. doi: 10.1097/RLI.0000000000000831.
Three-dimensional (3D) H-scan is a new ultrasound (US) technique that images the relative size of acoustic scatterers. The goal of this research was to evaluate use of 3D H-scan US imaging for monitoring early breast cancer response to neoadjuvant therapy using a preclinical murine model of breast cancer.
Preclinical studies were conducted using luciferase-positive breast cancer-bearing mice (n = 40). Anesthetized animals underwent US imaging at baseline before administration with an apoptosis-inducing drug or a saline control. Image data were acquired using a US scanner equipped with a volumetric transducer following either a shorter- or longer-term protocol. The later included bioluminescent imaging to quantify tumor cell viability. At termination, tumors were excised for ex vivo analysis.
In vivo results showed that 3D H-scan US imaging is considerably more sensitive to tumor changes after apoptosis-inducing drug therapy as compared with traditional B-scan US. Although there was no difference at baseline (P > 0.99), H-scan US results from treated tumors exhibited progressive decreases in image intensity (up to 62.2% by day 3) that had a significant linear correlation with cancer cell nuclear size (R2 > 0.51, P < 0.001). Results were validated by histological data and a secondary longitudinal study with survival as the primary end point.
Experimental results demonstrate that noninvasive 3D H-scan US imaging can detect an early breast tumor response to apoptosis-inducing drug therapy. Local in vivo H-scan US image intensity correlated with cancer cell nuclear size, which is one of the first observable changes of a cancer cell undergoing apoptosis and confirmed using histological techniques. Early imaging results seem to provide prognostic insight on longer-term tumor response. Overall, 3D H-scan US imaging is a promising technique that visualizes the entire tumor and detects breast cancer response at an early stage of therapy.
三维(3D)H 扫描是一种新的超声(US)技术,可对声散射体的相对大小进行成像。本研究的目的是使用临床前乳腺癌小鼠模型评估 3D H 扫描 US 成像在监测新辅助治疗早期乳腺癌反应中的应用。
在携带荧光素酶的乳腺癌小鼠(n=40)中进行了临床前研究。在给予凋亡诱导药物或生理盐水对照之前,麻醉动物在基线进行 US 成像。使用配备容积换能器的 US 扫描仪根据较短或较长的方案获取图像数据。后者包括生物发光成像以量化肿瘤细胞活力。在结束时,切除肿瘤进行离体分析。
体内结果表明,与传统 B 扫描 US 相比,3D H 扫描 US 成像对凋亡诱导药物治疗后肿瘤变化更为敏感。尽管在基线时没有差异(P > 0.99),但治疗后肿瘤的 H 扫描 US 结果显示图像强度逐渐下降(第 3 天高达 62.2%),与癌细胞核大小呈显著线性相关(R2 > 0.51,P < 0.001)。结果通过组织学数据和以生存为主要终点的二次纵向研究进行了验证。
实验结果表明,非侵入性 3D H 扫描 US 成像可以检测到早期乳腺癌对凋亡诱导药物治疗的反应。局部体内 H 扫描 US 图像强度与癌细胞核大小相关,这是癌细胞发生凋亡的最早可观察到的变化之一,并通过组织学技术得到证实。早期成像结果似乎为长期肿瘤反应提供了预后见解。总体而言,3D H 扫描 US 成像技术具有可视化整个肿瘤并在治疗早期检测乳腺癌反应的潜力。